

Anti-C-Kit Antibody-FITC (7P530)

Product Details

Ig Type:	Mouse IgG1
Reactivity:	Human
Conjugation:	FITC
Clone:	7P530
Purification:	Protein A

Applications

Verified Activity:	Flow cytometric analysis of Human KIT(CD117) expression on HEL92 cells. Cells were stained with FITC-conjugated anti-Human KIT(CD117). The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.
Application:	FCM
Recommended	5 µl/Test, 0.1 mg/ml

Properties

Stability & Storage:	Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight.
Shipping:	Shipping with blue ice.

Antigen Details

Immunogen:	Recombinant Protein: Human c-Kit Protein (TMPY-01935)
Antigen Species:	Human
Synonyms:	C-Kit;CD117;v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog;SCFR;PBT
Biology Area:	Cancer Drug Targets, Cardiac Stem Cell Markers, Receptor Tyrosine Kinases (RTKs)

Research Background

C-Kit is a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor). c-Kit contains 5 Ig-like C2-type (immunoglobulin-like) domains and 1 protein kinase domain. It belongs to the protein kinase superfamily, tyr protein kinase family, and CSF-1/PDGF receptor subfamily. C-Kit has tyrosine-protein kinase activity. Binding of the ligands leads to the autophosphorylation of KIT and its association with substrates such as phosphatidylinositol 3-kinase. Antibodies to c-Kit are widely used in immunohistochemistry to help distinguish particular types of tumor in histological tissue sections. It is used primarily in the diagnosis of GISTs. In GISTs, c-Kit staining is typically cytoplasmic, with stronger accentuation along the cell membranes. C-Kit antibodies can also be used in the diagnosis of mast cell tumors and in distinguishing seminomas from embryonal carcinomas. Mutations in the c-Kit gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous leukemia, and piebaldism. Defects in KIT are a cause of acute myelogenous leukemia (AML). AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development. Note= Somatic mutations that lead to constitutive activation of KIT are detected in AML patients. Cancer Immunotherapy Immune Checkpoint Immunotherapy Targeted Therapy

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481